Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.baylismedical.com
Number of Employees: 365
Year Founded: 1986
Total Amount Raised (CAD mm)†: 0.25
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Baylis Medical Company Inc. designs, manufactures, and distributes medical products for cardiology, pain management, and radiology applications. Its cardiology related products include RF puncture systems, RF transseptal needles, transseptal guiding sheaths, radiofrequency wires, microcatheters, and pigtail wires; endovascular related products comprise guide wires, crossing catheters, and RF puncture systems; and bone tumor pain management related products include RF ablation systems. The company also provides fixed electrophysiology catheters; and products used in transseptal punctures, endovascular occlusions, heart conditions, and bone cancer, as well as imports and distributes products of other manufacturers in Canada. It markets its products through distributors in Canada and internationally. Baylis Medical Company Inc. was incorporated in 1986 and is based in Montreal, Canada. It has additional offices in Mississauga, Canada; Austin, Texas; Boston, Massachusetts; Munich, Germany; Watford, United Kingdom; and Munich, Germany. As of February 14, 2022, Baylis Medical Company Inc. operates as a subsidiary of Boston Scientific Corporation.


Financial Information (Currency: CAD, in mm)
Total Revenue
 267.3
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 365
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Baylis, Frank 
Executive Chairman
Shah, Kris 
President & Director
Andrews, Howard 
Vice President of Finance & Accounting
Conquergood, Laura 
Vice President of Operations
Lifshitz, Nir 
Vice President of Intellectual Property & Legal
Wong, Michael 
Vice President of Global Marketing
Douma, Deborah 
Vice President of Human Resources

Key Board Members
Name
Title
Baylis, Frank 
Executive Chairman
Shah, Kris 
President & Director
Cunneen, Brendan 
Director
Gupta, Karna 
Director
Jamali, Vafa 
Member of Board of Advisors
Menawat, Arun Swarup
Member of Board of Advisors


Primary Industry Classification
Health Care Equipment


Primary Office Location
5959 Trans-Canada Highway | Montreal, QC | H4T 1A1 | Canada
Phone: 514-488-9801   Fax: 514-488-7209

Parent Company
Boston Scientific Corporation (NYSE:BSX)

Prior Investors
The Health Technology Exchange


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-06-2021
Feb-14-2022
Merger/Acquisition
Target
Baylis Medical Company Inc.
Boston Scientific Corporation (NYSE:BSX)

1,750.00
Apr-21-2011
Apr-21-2011
Private Placement
Target
Baylis Medical Company Inc.
The Health Technology Exchange

0.26
Jun-18-2010
Sep-13-2010
Merger/Acquisition
Seller
Attwell Capital Inc (nka:Citation Minerals Inc.)
0880650 B.C. Ltd.
Baylis Medical Company Inc.
0.33
Oct-2-2009
Oct-2-2009
Merger/Acquisition
Seller
Baylis Medical Company, Inc., Baylis RF Pain Management System
Kimberly-Clark Corporation (NYSE:KMB)
Baylis Medical Company Inc.
-
Mar-30-2009
Jun-1-2009
Merger/Acquisition
Buyer
Attwell Capital Inc (nka:Citation Minerals Inc.)
Baylis Medical Company Inc.

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Feb-14-2022
M&A Transaction Closings
Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Baylis Medical Company Inc.
Oct-06-2021
Corporate Guidance - New/Confirmed
Baylis Medical Company Inc. Provides Sales Guidance for the Year 2022
Oct-06-2021
M&A Transaction Announcements
Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Baylis Medical Company Inc. for $1.8 billion.
Aug-03-2021
Business Expansions
Baylis Medical Opens MedTech Facility in Costa Rica
Jul-29-2021
Product-Related Announcements
Baylis Medical Company Inc.  Announces First Clinical Use of the VersaCross® Large Access Solution to Deliver Large Bore Therapy Solutions

M&A Advisors
BCF LLP, Cooley LLP, Jefferies LLC, Norton Rose Fulbright Canada LLP, Piper Sandler Companies (NYSE:PIPR)


Advisors
M&A Advisors
BCF LLP, Cooley LLP, Jefferies LLC, Norton Rose Fulbright Canada LLP, Piper Sandler Companies (NYSE:PIPR)


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Jul 12, 2018 03:59 AM
Baylis Medical Company Inc.
Baylis Medical Company Inc
Reports
31
GlobalData

Jun 14, 2018 08:03 AM
Baylis Medical Company Inc.
Baylis Medical Company Inc
Reports
22
GlobalData

Mar 13, 2018 05:01 AM
Baylis Medical Company Inc.
Baylis Medical Company Inc
Reports
35
GlobalData

Dec 11, 2017 04:28 AM
Baylis Medical Company Inc.
Baylis Medical Company Inc
Reports
29
GlobalData

Sep 18, 2017 04:38 AM
Baylis Medical Company Inc.
Baylis Medical Company Inc
Reports
28
GlobalData

Jun 21, 2017 05:50 AM
Baylis Medical Company Inc.
Baylis Medical Company Inc
Reports
28
GlobalData

Mar 17, 2017 05:24 AM
Baylis Medical Company Inc.
Baylis Medical Company Inc.
Reports
18
GlobalData

Dec 05, 2016 05:04 AM
Baylis Medical Company Inc.
Baylis Medical Company Inc.
Reports
18
GlobalData

Sep 23, 2016 07:28 AM
Baylis Medical Company Inc.
Baylis Medical Company Inc.
Reports
18


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
EPstar, VersaCross Connect LAAC Access Solution, VersaCross Transseptal Platform

Key Board Members Details
Name
Title
Phone
Fax
Email
Baylis, Frank 
Executive Chairman
514-488-9801
514-488-7209

Shah, Kris 
President & Director
514-488-9801
514-488-7209

Cunneen, Brendan 
Director
514-488-9801
514-488-7209

Gupta, Karna 
Director
514-488-9801
514-488-7209
kgupta@certicom.com
Jamali, Vafa 
Member of Board of Advisors
514-488-9801
514-488-7209

Menawat, Arun Swarup
Member of Board of Advisors
(905) 629-3822
514-488-7209
amenawat@profoundmedical.com
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Baylis, Frank 
Executive Chairman
514-488-9801
514-488-7209

Shah, Kris 
President & Director
514-488-9801
514-488-7209

Andrews, Howard 
Vice President of Finance & Accounting
514-488-9801
514-488-7209

Conquergood, Laura 
Vice President of Operations
514-488-9801
514-488-7209

Lifshitz, Nir 
Vice President of Intellectual Property & Legal
514-488-9801
514-488-7209

Wong, Michael 
Vice President of Global Marketing
514-488-9801
514-488-7209

Douma, Deborah 
Vice President of Human Resources
514-488-9801
514-488-7209

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
